Neurotoxicity associated with anti-PD1 therapy: A multi-center case series.

Jess Louise Smith,Alexander M. Menzies,Justine V. Cohen,Margarida Mut Lioret,Alpaslan Ozgun,Lavinia Spain,John J. Park,Douglas B. Johnson,Jennifer Leigh McQuade,Sophie Feng,Shahneen Sandhu,Victoria Atkinson,Katy K. Tsai,Georgina V. Long,James Larkin,Zeynep Eroglu,Ryan J. Sullivan,Andrew Henderson,Matteo S. Carlino

Neurotoxicity associated with anti-PD1 therapy: A multi-center case series.

2017

Jess Louise Smith
Alexander M. Menzies
Justine V. Cohen
Margarida Mut Lioret
Alpaslan Ozgun
Lavinia Spain
John J. Park
Douglas B. Johnson
Jennifer Leigh McQuade
Sophie Feng
Shahneen Sandhu
Victoria Atkinson
Katy K. Tsai
Georgina V. Long
James Larkin
Zeynep Eroglu
Ryan J. Sullivan
Andrew Henderson
Matteo S. Carlino

e21641Background: The anti-PD1 antibodies (PD1) pembrolizumab and nivolumab are now FDA-approved in multiple malignancies. With increased use, rarer immune-related adverse events (irAEs) not well c...

Keywords:

Physical therapy
Neurotoxicity
Medicine
Pembrolizumab
anti pd1
Oncology
Internal medicine
Nivolumab
Adverse effect
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations